Compare PLAG & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAG | CVKD |
|---|---|---|
| Founded | 1986 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 17.0M |
| IPO Year | N/A | 2023 |
| Metric | PLAG | CVKD |
|---|---|---|
| Price | $3.64 | $6.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 229.9K | 54.0K |
| Earning Date | 11-14-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,494,847.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.47 | $6.42 |
| 52 Week High | $4.18 | $22.90 |
| Indicator | PLAG | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 62.25 | 33.95 |
| Support Level | $1.71 | $7.07 |
| Resistance Level | $4.18 | $8.21 |
| Average True Range (ATR) | 0.52 | 0.57 |
| MACD | 0.09 | -0.06 |
| Stochastic Oscillator | 78.13 | 7.89 |
Planet Green Holdings Corp is a diversified technology and consumer products company with a presence in North America and China engaged in Chemical Products, Tea Products, and Online Advertising Services. The company operates in three segments namely to grow, produce, and distribute Cyan brick tea, black tea, and green tea in China; to research, develop, manufacture, and sell chemical products including formaldehyde, urea formaldehyde adhesive, methylal, ethanol fuel, fuel additives and clean fuel in China; and to develop and operate a demand-side platform which empowers buyers of advertising to manage and optimize their digital advertising across different real-time bidding networks in North America and China.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.